Adamis pharmaceuticals announces receipt of deficiency letter from nasdaq

San diego, may 28, 2021 (globe newswire) -- adamis pharmaceuticals corporation (nasdaq: admp), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose (the “company”), today announced that, as expected, on may 25, 2021, it received a standard notification letter (the “notice”) from the listing qualifications department of the nasdaq stock market llc (“nasdaq”) notifying the company that, because the company did not timely file its quarterly report on form 10-q for the period ended march 31, 2021 (the “filing” or the “form 10-q”), the company is no longer in compliance with nasdaq marketplace rule 5250(c)(1), which requires timely filing of periodic reports with the securities and exchange commission (the “sec”).
ADMP Ratings Summary
ADMP Quant Ranking